Navigation Links
Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:11/30/2007

OXFORD, England, Nov. 30 /PRNewswire/ -- Chroma Therapeutics Limited announced today that it will report efficacy data from a Phase I clinical trial of its oral, once-daily experimental cancer therapy CHR-2797 at the forthcoming American Society of Hematology (ASH) meeting. CHR-2797 is the only oral aminopeptidase inhibitor currently in clinical development. The company will also be presenting the results of various preclinical studies. Details of the presentations are as follows:

Abstract # 443: oral presentation

Title: A Phase I Study of CHR-2797, an Orally Active Aminopeptidase

Inhibitor in Elderly and/or Treatment Refractory Patients with Acute

Myeloid Leukemia

Location and timing: Acute Myeloid Leukemias: Therapy, excluding

Transplantation-Novel Therapies, Rooms A411-A412: Monday December 10,

2007, 13:30-15:00 Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

Abstract # 1608, Poster # 762

Title: Cellular Aminopeptidase Inhibition as a Target for the Therapy of

AML by the Novel Agent CHR-2797

Location and timing: Poster Session I, Hall B4: Saturday, December 8,

2007, 17:30-19:30 Eastern Standard Time

Presenter: Dr Chris Jenkins (University Hospital, Cardiff, UK)

Abstract # 2505, Poster # 695

Title: Aminopeptidase Inhibition as a Targeted Treatment Strategy in

Myeloma

Location and timing: Poster Session II, Hall B4: Sunday, December 9,

2007, 18:00-20:00, Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

The ASH posters will be available at the company's website, http://www.chromatherapeutics.com following the above presentations.

Enquiries

Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles +44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.


'/>"/>
SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Multiple award ... been family-owned and operated for over 35 years. Maintaining core values of exceptional customer ... their success and made them a leading name in San Diego plumbing, and other ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor ... education and corporate training, and the National Military Family Association, a nonprofit that ... as the second full-tuition scholarship recipient of 2016. , “Being awarded this ...
(Date:5/6/2016)... ... 2016 , ... “ Crossing Over: Affirmations of Faith in the Midst of ... allowed those holding vigil to glimpse into the supernatural as their lives ended. With ... spiritually and practically gain insight into providing care to terminal patients. , “I ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession ... the impact our aging population has on communities and resources. Aging Life Care plays ... and face age-related challenges. , Aging Life Care is a holistic, client-centered approach ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is excited ... for public stakeholder review. The stakeholder review is an important opportunity for interested parties ... and delivers value to the wool industry., The RWS is intended to be a ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016  Compass Diversified Holdings (NYSE: ... owner of leading middle market businesses, announced today its ... 31, 2016. First Quarter 2016 Highlights ... ("CAD" or "Cash Flow") of $13.6 million for the ... of $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
Breaking Medicine Technology: